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Abstract
The purpose of the study was to identify characteristics
specific to tumor-derived endothelium that may be
important in tumor biology, or for the development of
targeted therapeutics or imaging agents. Normal
C57Bl/6 murine heart or lung endothelium, or C57Bl/6
murine Lewis lung carcinoma tumor–derived endothe-
lium was isolated from excised tissues using specific
antibodies. The endothelium was cultured using either
native fibronectin, or the oncofetal form of fibronectin.
Cell surface adhesion molecule expression was ana-
lyzed by flow cytometry, and the cellular distribution of
specific molecules was examined using indirect im-
munofluorescence staining. Oncofetal fibronectin was
critical for maintaining the phenotype of tumor-derived
endothelium, which demonstrated an elongated mor-
phology in vitro, with few cell–cell contacts. They
expressed high levels of CD31, CD102, and vascular
endothelial cadherin, and constitutively expressed
CD62E, CD54, and CD106, indicating an ‘‘activated’’
phenotype. Moreover, they expressed significantly
greater levels of Sca-1 and Flk-1 than normal murine
endothelium. Cellular distribution of CD31, B-catenin,
and CD106 in tumor-derived endothelium was not
continuous at cell borders, as observed in cultures of
murine heart endothelium. In conclusion, Lewis lung
carcinoma–derived tumor endothelium exhibits a
specific phenotype in vitro, distinct from normal
endothelium, and could be used as an in vitro tool for
developing targeted agents.
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Introduction
It has long been appreciated that the endothelium is an
active participant—and, in fact, mediates—many metabolic
processes and pathophysiologic responses within the vas-
cular system [1–3]. The normal endothelium, within a
variety of specialized tissues, exhibits particular character-
istics that can both define the location of the endothelium in
vivo and can govern the specific functions of that endothe-
lium within the host [4]. The microenvironment present within a
diseased or wounded tissue can influence the behavior of
resident endothelial cells (ECs), and may be reflected in
changes in cell surface expression of adhesion molecules, or
the production of cytokines or chemokines by ECs. Similarly,
the microenvironment present within a solid tumor is different
from that in the surrounding tissues [5,6], and it is now well
established that the phenotype of tumor microvasculature in
vivo differs widely from so-called ‘‘normal’’ endothelium in cell
surface adhesion molecule expression [7–10].
Until now, studies of tumor microvasculature have been
largely confined to in vivo studies in whole tumors or in ‘‘tumor
window’’ animal models [11], necessitated by the requirement
of the solid tumor environment to maintain the tumor endothe-
lium phenotype. Whereas these studies have provided valua-
ble insights into tumor growth, development, angiogenesis, and
vasculogenesis in vivo, there still remains a need to better
understand: 1) the profiles of tumor endothelium in different
tumor environments at both the gene and the protein level; 2)
the role of circulating cell recruitment in tumor growth and
vasculogenesis; and (3) the function of specific cell adhesion
molecules, chemokines, and cytokines within the tumor envi-
ronment. The heterogeneous nature of the solid tumor and the
presence of a variety of different cell types within the neoplastic
tissue make it particularly difficult to isolate specific genes, for
example, that are expressed within the tumor endothelium per
se, or to identify the source of chemokines within the tumor
environment. Similarly, the behavior of circulating cells across
tumor endothelium can be investigated only within the small
vessels of the tumor margins that can be visualized using
intravital microscopy [11,12]. The ability to both isolate tumor-
derived ECs from a variety of tumor types and to be able to
maintain the tumor-specific phenotype in vitro would provide
an ideal model to investigate some of these processes.
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Furthermore, such models would facilitate the high through-
put screening of antiendothelial therapeutic agents.
In previous studies, tumor-derived endothelium has been
isolated from either MCF-7 human breast cancer cells
implanted into nude mice [13], or from human neoplastic
tissue samples [14]. These studies were extremely useful in
defining certain conditions for high-purity isolation of tumor-
derived ECs; however, there are a number of caveats to
these approaches. In the first case, the isolation involved a
large number of successive cell-sorting steps of CD31+ cells,
resulting in a low yield. In addition, the population was not
cultured in vitro and endothelial identity was not confirmed by
additional endothelial markers. Alessandri et al. [14] suc-
cessfully isolated tumor-derived endothelium from human
neoplastic specimens; however, due to the nature of the
source tissue and the ability to culture these endothelia for
only a short time in vitro, this method does not provide a
suitable model for ongoing in vitro studies.
Here we describe the isolation and in vitro culture of
tumor-derived endothelium from C57Bl/6 murine Lewis lung
carcinoma (LLC), and the comparison of these cells to
normal C57Bl/6 endothelium isolated simultaneously. Impor-
tantly, this model allows for successive generations of tumor-
derived endothelia from the same source (i.e., C57Bl/6 mice
carrying LLCs). The tumor-derived endothelium is directly
comparable to the control ECs as they are derived from
syngeneic animals at the same time as the tumor-derived
endothelium. A significant problem in isolating endothelia
from individual sources in the past has been the ability to
maintain the specialized phenotype in vitro. Just as endo-
thelia derived from different vascular beds in the normal
animal exhibit differences in phenotype [15], we hypothe-
sized that tumor-derived endothelia would necessarily dem-
onstrate significant phenotypic differences compared to
normal ECs [16], and that maintaining these differences
would be critical to developing an in vitro model of tumor
endothelium. Using specialized tumor-specific extracellular
matrix (oncofetal fibronectin, OnFN), we have been able to
maintain the phenotype of the tumor-derived endothelia in
culture. These cultures can thus now be used for a variety of
in vitro experiments to evaluate the function of tumor-derived
endothelium and to analyze tumor-specific characteristics
under controlled conditions. Moreover, we have identified
specific characteristics of tumor-derived endothelia, which
may be important in understanding the biology of tumor
microvasculature in vivo and may have potential importance
as targets for therapeutic or imaging agents.
Materials and Methods
Materials
DMEM, 1 M HEPES solution, nonessential amino acids,
sodium pyruvate solution, sodium bicarbonate solution, Dul-
becco’s phosphate-buffered saline (DPBS), DPBS with Ca2 +
and Mg2 + (DPBS+), Hanks balanced salts solution (HBSS),
and RPMI-1640 were purchased from Biowhittaker Bioprod-
ucts (Walkersville, MD). Fetal calf serum (FCS) was pur-
chased from Cellgro (Herndon, VA). Recombinant murine
tumor necrosis factor-a (mTNF-a) and recombinant murine
vascular endothelial growth factor (VEGF) were purchased
from R&D Systems (Minneapolis, MN) and contained less
than 10 pg/ml endotoxin, as determined by themanufacturer.
Human fibronectin (hFN) was purchased from BD Biosci-
ences (Bedford, MA). All other chemicals were of the highest
grade available from either Fisher Scientific (Suwanee, GA)
or Sigma (St. Louis, MO).
Antibodies
The following antibodies were obtained from BD Pharmin-
gen (San Diego, CA): purified antimouse CD31 (rat IgG2a,
cloneMEC 13.3), PE-conjugated antimouseCD31 (rat IgG2a,
clone MEC 13.3), purified antimouse intercellular adhesion
molecule (ICAM)-2 (CD102, rat IgG2a, clone 3C4), purified
antimouse Flk-1 (VEGFR2, rat IgG2a, clone Avas 12a1),
purified antimouse CD106 [vascular cell adhesion molecule
(VCAM)-1, rat IgG2a, clone 429], purified antimouse CD54
(ICAM-1, hamster IgG, clone 3E2), purified antimouse vas-
cular endothelial (VE)-cadherin (CD144, rat IgG2a, clone
11D4.1), purified antimouse CD62E (E-selectin, rat IgG2a,
clone 10E9.6), and PE-conjugated antimouse Ly-6A (Sca-1,
rat IgG2a, clone E13-161.7). Purified rabbit polyclonal IgG
anti–h-catenin (rabbit IgG) was purchased from Upstate
Biotechnologies (Lake Placid, NY). Streptavidin-conjugated
Cy-Chrome and biotin-conjugated mouse–antihamster IgG
(mouse IgG, clone G94-56) were obtained from BD Pharmin-
gen. FITC-conjugated goat F(abV)2 antirat IgG (H+L) and
streptavidin-conjugated APCwere obtained fromCaltag Lab-
oratories (Burlingame, CA). Texas Red–conjugated goat–
antirat IgG, FITC-conjugated goat–antirabbit IgG (H+L), and
Texas Red–conjugated goat–antirabbit IgG (H + L) were
purchased from Vector Laboratories (Burlingame, CA). Bio-
tinylated antirat IgG (H+L) was purchased from Jackson
Immunoresearch Laboratories (West Grove, PA).
Mice
C57Bl/6 wild-type mice were purchased from National
Cancer Institute, NIH, Bethesda, MD. All mice were main-
tained in our approved pathogen-free and viral-free institu-
tional housing facilities. Mice were used between 6 and
16 weeks of age (20–25 g) for all isolations. Animals were
sacrificed by overdose of anesthesia (ketamine/xylazine) by
intraperitoneal injection, as approved by the panel on Eutha-
nasia at the American Veterinary Association.
Purification of OnFN
OnFN was purified from the conditioned medium of WI38-
VA13 cells (American Type Culture Collection, Manassas,
VA), as described previously [17]. Briefly, 10 l of medium
(EMEM containing 10% FCS) was precleared of endogenous
fibronectin by passage over a large-capacity (200 ml) gelatin
sepharose (Sigma) column. The medium was then immedi-
ately filter-sterilized, and 1 mM sodium pyruvate, 0.1 mM
nonessential amino acids, 1.5 g/l NaHCO3, 1 mM L-gluta-
mine, antibiotics, and 10 AM dexamethasone were added.
WI38-VA13 cells were cultured to confluence in a cell culture
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factory (6350 cm2; Nalge Nunc International, Rochester, NY)
and then fed every 4 days with fresh precleared complete
medium in 1 l volumes. Conditioned medium was filtered
immediately to remove dead cells and passed over a similar
gelatin sepharose column to extract the fibronectin isoforms.
Column-bound fibronectin was eluted with 8 M urea in 50 mM
Tris, pH 7.5, and 25 ml fractions were collected. Those with
maximum absorbance at 280 nm were pooled, dialysed into
PBS, filter-sterilized, and stored in 1 ml aliquots at  80jC.
Cell Culture
LLC cells The LLC cell line derived from an LLC of C57Bl/6
mouse was purchased from ATCC. Cells were cultured in
DMEM containing 10% FCS, sodium bicarbonate, L-gluta-
mine, and antibiotics, and split at a ratio of 1:10 every 3 to
4 days. Confluent monolayers of LLC were used for implan-
tation of tumors in C57Bl/6 mice, and conditioned medium
from LLC was recovered and frozen at  80jC for culture of
tumor endothelium.
Isolation and culture of normal murine heart endothelial cell
(MHEC) or murine lung endothelial cell (MLEC) endothelium
Normal MHECs or MLECs were isolated using a modification
of previously published methods [18]. Briefly, the hearts of
three mice were harvested, minced finely, digested in 25 ml
of collagenase [2 mg/ml (wt/vol) in HBSS; Worthington
Biochemical, Lakewood, NJ] at 37jC for 45 minutes and
filtered through a 70 Am disposable cell strainer (Fisher
Scientific). Cells were resuspended in 1 ml of DPBS+ and
the concentration was adjusted to 3 107 cells/ml crude EC
preparation. Sheep–antirat IgG Dynal beads (Dynal, Great
Neck, NY) were coated with anti-CD31 mAb according to the
manufacturer’s instructions. The crude cell preparation was
incubated with anti–PECAM-1-coated beads (35 Al/ml cells)
at room temperature (RT) for 10 minutes with end-over-end
rotation. The bead-bound cells were recovered magnetically,
washed with DMEM containing 20% FCS, suspended in 12
ml of complete culture medium [DMEM containing 20% FCS,
supplemented with 100 Ag/ml porcine heparin, 100 Ag/ml
ECGS (Biomedical Technologies, Stoughton, MA), nones-
sential amino acids, sodium pyruvate, L-glutamine, and anti-
biotics] and then plated in a single gelatin-coated 75 cm2
tissue culture flask. After overnight incubation in a standard
5% CO2 incubator, the nonadherent cells were removed,
adherent cells washed with HBSS, and then 12 ml of fresh
complete medium was added. Cultures were fed routinely on
alternate days with fresh complete culture medium until they
reached confluence. At this point, MLECs were further sorted
using anti– ICAM-2 (CD102) beads and plated to fresh
gelatin-coated flasks. Confluent monolayers of MHECs or
MLECs were used at passages 1 to 3.
Isolation and culture of LLC tumor-derived endothelium
(TEC) C57Bl/6 mice (male, 8–12 weeks) were implanted
subcutaneously and bilaterally in the flank with 5 106
LLCs in 100 Al of normal saline. Tumors were allowed to
reach approximately 1 cm in diameter, at which point
animals were sacrificed and the tumor capsules were
removed. Tumors were washed in three exchanges of
LLC medium and then chopped into small pieces and
digested with 30 ml of collagenase (2 mg/ml in HBSS)
per six tumors for 60 minutes at 37jC with mixing. The
tissue was mechanically disrupted by titrating through a 14-
gauge blunt-end needle and the resulting cell suspension
was filtered through a 70 Am pore size filter. Sheep–antirat
IgG Dynal beads were coated with anti-CD31 mAb accord-
ing to the manufacturer’s instructions. Pelleted cells were
resuspended at 30 106/ml in DPBS+ and incubated with
7 106 CD31-specific beads per milliliter of cell suspension
for 10 minutes at RT with end-over-end rotation. Bead-bound
cells were isolated magnetically and plated to a 1 75 cm2
flask precoatedwithmurine collagen IV (BDBiosciences) and
either 1 Ag/cm2 OnFN or 1 Ag/cm2 hFN in LLC-conditioned
medium containing an additional 10% FCS (total 20%),
L-glutamine, nonessential amino acids, sodium pyruvate, 100
Ag/ml porcine intestinal heparin, 100 Ag/ml ECGS, and anti-
biotics. After overnight culture, the nonadherent cells were
removed and the fresh medium containing 10 ng/ml VEGF
was added. Cells were fed every 2 to 3 days until obvious EC
colonies of 10 or more cells per colony were apparent
(approximately 60% confluence). At this time, cells were
washed extensively with HBSS and detached with trypsin–
EDTA. Any cells not detaching after 2 minutes of incubation
with trypsin were discarded. Sheep–antirat IgG Dynal beads
were coated with anti– ICAM-2 mAb according to the manu-
facturer’s instructions. Cells were resuspended in 2 ml of
DPBS+ and incubated with 7 106 beads for 10 minutes at
RT with end-over-end rotation. Bead-bound cells were iso-
lated magnetically and plated to 2 60 mm-diameter dishes
precoated with murine collagen IV and 1 Ag/cm2 of either
OnFN or hFN (subculture 1). Cells were fed every 2 to 3 days
until they reached confluence and then used in experiments
at subcultures 1 or 2.
Immunohistochemistry of LLC C57Bl/6 mice were
implanted bilaterally in the flank with 5 106 LLCs. Once
the tumors had reached approximately 0.5 cm, they were
excised, fixed for 2 hours in 2% paraformaldehyde in PBS on
ice, and then equilibrated overnight in 18% sucrose in PBS at
4jC. Tumors were then embedded in OCT, snap-frozen in
liquid N2, and divided into 10 Am sections. Serial sections
were stained with antibodies to CD31, CD102, CD144,
CD106, Flk-1, and CD62E at 1 Ag/ml, detected with biotiny-
lated antirat IgG, and developed with the NovaRED substrate
kit (Vector Laboratories). Control sections were stained with
secondary antibody only. All sections were counterstained
with Gill’s hematoxylin no. 2 (m), dehydrated in ethanol, and
mounted with Permount (Fisher Scientific). Digital images
were taken at  20 objective using a Nikon upright micro-
scope equipped with an Insight CCD camera.
Flow cytometric analysis of cell surface protein expression
Cell surface protein expression was analyzed using a mod-
ification of published protocols [19]. Confluent monolayers of
MHEC, MLEC, or TEC (subculture 1) in 60 mm dishes
coated with either collagen IV/hFN or collagen IV/OnFN
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were stimulated with either 120 ng/ml mTNF-a or vehicle
alone for 5 hours at 37jC. Monolayers were washed exten-
sively with warm (37jC) HBSS to remove serum and then
suspended by brief (60 seconds) trypsinization in 1 ml of
prewarmed (37jC) trypsin–EDTA. Proteolysis was arrested
by the addition of 5 vol of ice-cold RPMI-1640 containing
20% FCS. ECs were then pelleted and resuspended in ice-
cold RPMI-1640 containing 5% FCS (5% RPMI). Analysis of
cell surface expression of CD31 and Sca-1 was performed
using a single-step immunofluorescence staining utilizing
anti–CD31–PE and anti–Sca-1–PE conjugates, respec-
tively (10 Ag/ml, 30 minutes on ice). Analysis of cell surface
expression of ICAM-2, VCAM-1, E-selectin, VE-cadherin,
and Flk-1 was performed using a two-step staining proce-
dure with purified antigen-specific mAb (10 Ag/ml, 30minutes
on ice), three washes with 1 ml of 5% RPMI followed by
detection with FITC antirat IgG (1/50 dilution, 30 minutes on
ice). Analysis of ICAM-1 was performed using a three-step
procedure with anti–ICAM-1 mAb (10 Ag/ml, 30 minutes on
ice), washed as above, incubated with biotinylated antiham-
ster IgG (10 Ag/ml, 30minutes on ice), washed a further three
times with 5% RPMI, and finally detected with streptavidin-
conjugated APC (1/50 dilution, 30 minutes on ice). In all
cases, the cells underwent a final two washes with 5% RPMI:
one wash with DPBS and fixation in 2% paraformaldehyde. A
minimum of 10,000 cells per sample was analyzed on a
BectonDickinson FACScan (BDBiosciences, San Jose, CA).
Indirect immunofluorescence analysis of endothelial
proteins MHECs or TECs at subculture 2 were plated on
OnFN-coated (1 Ag/cm2) 12-mm-diameter glass coverslips
and allowed to reach confluence. Monolayers were washed
2 with DPBS+ and then fixed in 100% ice-cold methanol for
5 minutes at  20jC, and washed a further 3 in DPBS+.
Monolayers were blocked in Tris-buffered saline [10 mM
Tris, 150 mM NaCl (TBS)], pH 7.4, containing 0.1 mg/ml
salmon sperm DNA, 1% (vol/vol) horse serum, and 1% (vol/
vol) goat serum (block) for 20 minutes at 37jC. Monolayers
were then incubated for 45 minutes at 37jC with specific
mAb (5–10 Ag/ml in block), rinsed 3 in DPBS+, and
incubated with either goat–antirat IgG–Texas Red, goat–
antirabbit IgG–FITC, or goat–antirabbit IgG–Texas Red (1/
100 dilution in block) for 45 minutes at 37jC. Monolayers
were washed 2 with DPBS+, 1 with dH2O, and mounted
with Vectashield (Vector Laboratories). Immunofluorescence
staining was visualized on a Zeiss Axiovert inverted micro-
scope equipped for fluorescence and with a  40 objective.
Images were captured using a cooled charge-coupled device
(CCD) video camera (Sensys; Photometrics) and IP Labo-
ratories Spectrum software (Scanalytics, Vienna, VA).
Results
LLC Vessels Exhibit Constitutive Expression of Inducible
Endothelial Adhesion Molecules In Situ
C57Bl/6 mice were implanted bilaterally in the flank with
5 106 LLCs. Once the tumors had reached approximately
0.5 cm, they were excised, processed for immunohistochem-
istry as described in Materials and Methods section, and
serial sections were stained with antibodies directed
against CD31 (PECAM-1), CD102 (ICAM-2), CD144 (VE-
cadherin), CD106 (VCAM-1), VEGFR2 (Flk-1), and CD62E
(E-selectin). Controls were stained with secondary antibody
only. As shown in Figure 1, antibodies to the endothelial
markers CD31 (panel a), ICAM-2 (panel c), and VE-cadherin
(panel e) were observed to strongly stain the endothelium in
the vessel walls of the tumor vasculature, and no staining
was observed in other intratumoral locations or in the control
serial sections. Flk-1 expression (Figure 1j ) was also
restricted to the vessel walls and stained strongly, implying
that the endothelium within tumor vessels has a high expres-
sion of VEGFR2. In contrast, VCAM-1 (Figure 1g ) was
identified throughout the tumor, and was not restricted to
the vessel walls, suggesting that tumor cells also express
high levels of VCAM-1, perhaps as part of their ability to
mimic the vasculature. Expression of E-selectin appeared to
be restricted to smaller vessels, but was constitutively
expressed (Figure 1m), which is in contrast to that observed
in normal vessels, suggesting that the tumor vessels were
exhibiting an ‘‘activated’’ phenotype.
Tumor-Derived Endothelium and Normal Endothelium Have
Different Morphologies In Vitro That Are Partially Dependent
on Culture Substrate
MHEC-, MLEC-, or LLC-derived tumor endothelial cells
(TEC) at subculture 1, following the second selection with
anti– ICAM-2–specific beads, were plated on collagen IV–
coated 60 mm dishes that had been precoated with either
OnFN or hFN for 60 minutes at RT. The morphologies of the
resulting cultures are demonstrated in Figure 2. As can been
seen in Figure 2, normal MHECs (Figure 2A) or MLECs
(Figure 2C) cultured on collagen IV/hFN have a ‘‘typical’’
endothelial cobblestone morphology, reminiscent of human
umbilical vein endothelium in vitro. The cells are uniform in
size, and there is tight apposition between neighboring cells,
suggesting the presence of cell–cell junction complexes.
The cells proliferate at a moderate rate and are completely
contact-inhibited. When MHECs or MLECs were plated on
collagen IV/OnFN, there was no significant difference in their
morphology compared to cells plated on collagen IV/hFN
(Figure 2, B andD, respectively). In contrast, the morphology
of TECs cultured on collagen IV/OnFN differs significantly
from normal MHECs or MLECs. As can be seen in Figure 2F,
the ECs are extremely elongated and do not form the tight
cobblestone monolayer seen in Figure 2, A–D. Their pro-
liferation rate is much lower than that observed for normal
MHECs or MLECs. In addition, the cell–cell contacts appear
tenuous, at best. This morphology is perhaps not surprising
considering that tumor endothelium in vivo is considered to
be much more leaky than endothelium in normal tissue
environments [20]. In addition, their nuclei are noticeably
larger with less condensed chromatin. Notably, when TECs
were plated onto collagen IV and adult hFN (Figure 2E ), the
morphology of the cells was different again. These cells were
selected by CD31 and ICAM-2 expression markers in a
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similar manner to either normal endothelium or TECs plated
onto OnFN, but they failed to form cell–cell contacts and did
not approach a monolayer appearance. They proliferated
very rapidly compared with TECs plated on OnFN, but were
also shed from the culture surface rapidly, with much mem-
brane blebbing, thus never reaching a confluent monolayer.
Figure 1. LLC exhibits constitutive expression of inducible endothelial adhesion molecules in vivo. LLCs were grown in C57Bl/6 mice, excised, and processed for
immunohistochemistry as described in Materials and Methods section. Tumor sections were stained with antibodies to (a) CD31, (c) ICAM-2, (e) VE-cadherin, (g)
VCAM-1, (j) Flk-1, and (m) E-selectin. Serial control sections were stained with 2 V Ab only (panels b, d, f, h, k, n). Sections were counterstained with Gill’s
hematoxylin no. 2. Digital images were taken at  20 objective using a Nikon upright microscope equipped with an Insight CCD camera and using Spot Advance
software. Images are representative of two tumors from two different animals.
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Their nuclei comprised a larger proportion of the cell volume
than normal endothelium, with more diffuse chromatin.
Tumor-Derived Endothelium Requires Tumor-Specific
Extracellular Matrix to Maintain Expression of EC Markers
In Vitro
TECs were plated at subculture 1 onto 60 mm dishes
precoated with collagen IV and either OnFN or hFN. The
cells were allowed to reach 75% to 95% confluence and
then analyzed by flow cytometry for cell surface markers
of endothelium (CD31, ICAM-2, and VE-cadherin), as
described in Materials and Methods section. As can be seen
in Figure 3, TECs plated on OnFN were >95% double-
positive for both CD31 and ICAM-2, with one distinct pop-
ulation (top left panel). In addition, the CD31+/ICAM-2+ cells
are 97% positive for VE-cadherin (filled graph, bottom left
panel) when compared to an isotype-matched control anti-
body (open graph). This expression profile did not change
over time within the same subculture or in subsequent
subcultures (subculture 2 or 3) of the same population (data
not shown). In contrast, TECs plated onto a combination of
collagen IV and hFN demonstrated that only 38% of the
population was positive for both CD31 and ICAM-2 (Figure 3,
top right). Of the CD31+/ICAM-2+ cells, only 42% were
positive for VE-cadherin (Figure 3, bottom right). Whereas
the mcf for the positive population (mcf 77; Figure 2, bottom
Figure 2. The morphology of tumor endothelium is distinct from normal endothelium and dependent on extracellular matrix. MHECs, MLECs, and TECs were
isolated from murine heart, murine lung, or murine LLC, respectively, as described in Materials and Methods section. MHECs, MLECs, or TECs at subculture 1
were plated on a combination of either collagen IV and 1 lg/cm2 OnFN (panels B, D, F) or collagen IV and 1 lg/cm2 hFN (panels A, C, E). Once the endothelium
had reached near confluence (95%), phase contrast micrographs of the cultures were taken using an Axiovert inverted microscope equipped with a  20 phase
contrast objective. As can be seen in panels A–D, normal MHECs or MLECs exhibit a ‘‘typical’’ cobblestone morphology, with uniform cell size and close cell – cell
contacts, and there is no obvious difference in morphology between cells plated on hFN (A, C) or cells plated on OnFN (B, D). In contrast, TECs (panels E and F)
are extremely elongated in appearance with tenuous cell – cell contacts. TECs cultured on collagen IV and hFN (panel E) do not form typical endothelial
monolayers, but instead remain rounded and both proliferate and die rapidly in culture, suggesting a requirement for the oncofetal form of fibronectin in vitro.
Images are representative of >10 cultures in each case, derived from different tumors or heart tissues on different days. Magnification,  20 objective.
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right) was not significantly different from the mcf for VE-
cadherin expression of TECs when plated on OnFN (mcf 87;
Figure 3, bottom left), >50% of the TECs plated on hFN did
not express VE-cadherin. In addition, it was important to note
that as the culture aged, or in subsequent subcultures of
the same population, the number of CD31/ICAM-2 double-
positive cells decreased further and the mcf for VE-cadherin
expression declined (data not shown), indicating a require-
ment for OnFN to maintain the endothelial phenotype of
TECs. Indeed, when confluent monolayers of TECs, origi-
nally plated on collagen IV and OnFN, were subcultured on
hFN, they rapidly lost their tumor-specific phenotype (data
not shown), indicating a requirement for the specialized
matrix throughout their culture. In contrast, normal MHECs
or MLECs plated on collagen IV/hFN or gelatin maintain their
endothelial phenotype throughout subcultures 1 to 4 (data
not shown).
Tumor-Derived Endothelium Expresses Increased Levels of
EC Markers When Compared to Normal Endothelium
MHECs, MLECs, or TECs (subculture 1) plated on a
combination of collagen IV and OnFN were allowed to reach
90% confluence and then cell surface markers were ana-
lyzed by flow cytometry as described in Materials and
Methods section. TECs were 99%, 99%, and 98% positive
for CD31, ICAM-2, and VE-cadherin, respectively (Figure 4,
filled graphs), similar to that reported above. Normal
MHECs demonstrated a 97%, 73%, and 60% positive
population for CD31, ICAM-2, and VE-cadherin, respec-
tively (Figure 4, open graphs), with a small population of
cells that did not express these markers. Similarly, MLECs
demonstrated a 99%, 90%, and 73% positive population for
CD31, ICAM-2, and VE-cadherin, respectively. Importantly,
when all three markers were examined at the same time on
the same cells using triple staining procedures, MHEC or
MLEC populations were >80% positive for all three markers
(data not shown), and the ratio of nonexpressing cells to the
positive population did not change over time within the
culture or subsequent subcultures [2,3] of the same pop-
ulation (data not shown). Interestingly, not only was the
TEC population of greater purity than the normal endothelial
populations, but the relative mcf for each marker was
significantly greater on TECs than on MHECs or MLECs;
that is, TECs had an mcf of 396, 177, and 84 for CD31,
ICAM-2, and VE-cadherin, respectively, whereas MHECs
had an mcf of 61, 44, and 18 and MLECs had an mcf of 236,
33, and 16, respectively for the same markers, indicating
that cell surface expression of these endothelial markers is
greater on TECs than on normal endothelium. When
MLECs or MHECs were plated on hFN or gelatin rather
than OnFN, and/or cultured in the presence of TEC-specific
medium, no significant difference in cell surface expression
was observed (data not shown). The differences in cell
surface expression between TECs and normal ECs are
not likely to be explained by murine strain differences as
TECs are derived from a C57Bl/6 mouse LLC, grown in a
C57Bl/6 host, and compared to heart-derived endothelium
from normal C57Bl/6 mice, but are more likely to indicate
true differences in cell surface expression between the two
types of endothelium.
Figure 3. Characterization of tumor endothelium in the presence of OnFN or hFN. TECs were plated at subculture 1 onto 60 mm dishes precoated with either
collagen IV/OnFN or collagen IV/hFN. Cells were allowed to reach 75% to 90% confluence and then were detached by rapid trypsinization and analyzed for cell
surface markers by flow cytometry. As can be seen in the top left panel, TECs plated on OnFN were >95% double-positive for CD31 and ICAM-2; in addition, they
were >95% positive for VE-cadherin, with an mcf = 87 (bottom left, filled graph). These markers indicate an extremely pure population of endothelial cells. In
contrast, TECs plated on hFN were only 38% double-positive for CD31 and ICAM-2, with a distinct negative population. Of the CD31+/ICAM-2+ cells, only 42%
exhibited expression of VE-cadherin (bottom right, filled graph). These data indicate that the presence of oncofetal fibronectin is essential in vitro to maintain the
endothelial phenotype of TECs. These data are representative of three similar experiments performed on separate days with different endothelial cultures. A
minimum of 10,000 cells per sample was analyzed and compared to an isotype-matched control antibody (open graphs).
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In addition to classic EC surface markers, we examined
also the cell surface expression of Sca-1 (murine equivalent
of human CD34) and VEGF receptor 2 (Flk-1) on TECs,
MHECs, or MLECs. Whereas all populations showed a
significant percentage of cells positive for Sca-1 (TEC=
99%, MHEC=96%, and MLEC=98%; Figure 4), the TEC
population expressed much greater levels of Sca-1 on their
cell surface than either MHEC or MLEC (mcf = 255 for TEC,
mcf = 132 for MHEC, mcf = 77 for MLEC; Figure 4). High
levels of Sca-1 expression may indicate that tumor-derived
endothelium in this model originates from the recruitment of
host-derived precursor cells to the growing tumor, consistent
with the idea of circulating endothelial progenitors being
recruited to tumors to increase tumor angiogenesis and
vasculogenesis [21]. Conversely, the low level of Sca-1
expression in normal endothelium may indicate that these
endothelia are derived from an adult tissue origin, with little or
no recruitment of circulating progenitors to the tissue.
Consistent with the hypothesis that tumor endothelium in
carcinomas in vivo is rapidly dividing and responds to VEGF
induction [22–24], the cell surface expression of Flk-1 on
TEC was significantly greater than on normal endothelium.
TECs were >97% for Flk-1 expression with an mcf of 35,
whereas normal MHECs were only 22% positive with a
strikingly lower level of expression (mcf = 6; Figure 4). In
contrast, MLECs exhibited a >80% positive population, with
a similar level of Flk-1 expression (mcf = 32), suggesting that
the origin of the tissue, whether it be normal or malignant,
may contribute to expression of Flk-1 (i.e., that lung-derived
endothelium in our hands maintains the potential to respond
to VEGF). Again, the type of extracellular matrix (OnFN,
hFN, gelatin) or the presence of tumor-specific medium had
no effect on cell surface expression in MHECs or MLECs
(data not shown).
Tumor-Derived Endothelium Exhibits a Constitutively
Activated State In Vitro
The morphology of TECs in vitro, elongated cells with little
cell–cell contact, appeared reminiscent of normal endothe-
lium that had been activated with cytokines (e.g., TNF-a) to
induce cell surface expression of adhesion molecules. We
were interested, therefore, in whether TECs expressed
similar or greater levels of classic adhesion molecules than
normal endothelium. Normal MHECs or MLECs plated on
collagen IV/OnFN at subculture 1 were incubated in the
presence or absence of 120 ng/ml mTNF-a for 5 h. TECs
were plated at subculture 1 on a combination of either
collagen IV and OnFN, or collagen IV and adult hFN.
MHECs, MLECs, and TECs were analyzed by flow cytometry
for their cell surface expression of E-selectin (CD62E),
ICAM-1, and VCAM-1.
Normal MHECs or MLECs constitutively expressed some
degree of ICAM-1 and VCAM-1 (Figure 5) with >60% MHEC
and >40% MLEC populations positive in the absence of
cytokine induction. MHECs expressed significant levels of
VCAM-1 (mcf = 107) andMLECs expressed significant levels
of ICAM-1 (mcf = 212). This is in contrast to that observed for
human umbilical vein endothelium, where VCAM-1 is not
constitutively expressed in vitro and only low levels of
ICAM-1 are observed [25]. For both MHECs and MLECs,
the cell surface expression of E-selectin, ICAM-1, and
VCAM-1 could be significantly increased by the presence of
Figure 4. TECs express greater levels of endothelial adhesion molecules than normal endothelium. TECs, MHECs, or MLECs were plated at subculture 1 onto
60 mm dishes precoated with collagen IV/OnFN. Once cells had reached approximately 90% confluence, they were detached by rapid trypsinization and analyzed
for cell surface markers by flow cytometry. TECs (filled graphs) consistently expressed greater levels of CD31 (mcf = 362), ICAM-2 (mcf = 177), and VE-cadherin
(mcf = 84) than MHECs (open graphs; mcf = 60, 44, and 18, respectively) or MLECs (dotted line; mcf = 236, 33, and 16, respectively). In addition, TECs exhibited a
higher-purity single population (>95%) than MHECs or MLECs, which consistently demonstrated a nonexpressing population in all experiments (10–15%). TECs
(filled graphs) and MHECs (open graphs) or MLECs (dotted line) expressed Sca-1 and Flk-1; however, TECs expressed substantially greater levels of both
markers on their cell surface than MHECs or MLECs. Data are representative of three similar experiments performed on separate days with different endothelial
cultures. A minimum of 10,000 cells per sample was analyzed. All data were compared to an isotype-matched control antibody (top left panel).
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mTNF-a (Figure 5, middle panels; Table 1). In the presence
of TNF-a, the mcf for E-selectin expression was 57, for
ICAM-1 was 238, and for VCAM-1 was 312 in MHEC,
greater than 3 that observed in resting endothelium. In
MLECs, TNF-a induced a significant increase in E-selectin
(mcf = 52) and VCAM-1 (mcf = 81) expression and a
limited induction of ICAM-1 (mcf = 251). Culture of MHECs
or MLECs on hFN or gelatin or culture in the presence of
tumor-specific medium and VEGF did not significantly
affect expression of the endothelial molecules examined
(data not shown). TECs plated on OnFN demonstrated a
constitutively high percent positive population (>97% in all
cases) and greater expression levels of all three adhesion
molecules examined when compared to TECs plated on
hFN (Figure 5, upper panels; Table 1). Furthermore,
OnFN-plated TECs expressed similar levels of E-selectin
to mTNF-a–induced normal MHECs or MLECs (mcf = 49,
52, and 57, respectively) and significantly greater levels of
ICAM-1 (mcf = 604, 238, and 251, respectively), indicating
that TECs plated on OnFN are in a constitutively activated
state in vitro. The addition of mTNF-a to cultures of TEC
did not further increase the levels of adhesion molecule
expression (data not shown).
TEC Demonstrates Different Cellular Distributions of
Endothelial and Junctional Proteins When Compared to
Normal MHEC
Confluent monolayers of either normal MHECs or TECs
(subculture 2) plated on glass coverslips were stained for the
presence of CD31, h-catenin, ICAM-2, or VCAM-1 as
described above. Both MHECs and TECs expressed each
Figure 5. TECs constitutively express markers of endothelial activation in vitro. TECs, MHECs, or MLECs were plated at subculture 1 onto 60-mm dishes
precoated with either collagen IV/OnFN, or collagen IV/hFN (TECs only). Once cells had reached approximately 90% confluence, MHECs or MLECs were
incubated in the presence or absence of 120 ng/ml mTNF-a for 5 hours prior to analysis. All populations were then detached by rapid trypsinization and analyzed
for cell surface markers by flow cytometry. In the upper panels, TECs plated on OnFN (filled graphs) were compared to TECs plated on hFN (open graphs). In the
middle panels, MHECs (filled graphs) were compared to MHECs activated with mTNF-a (open graphs). In the bottom panels, MLECs (filled graphs) were
compared to MLECs activated with mTNF-a (open graphs). TECs cultured in the presence of OnFN consistently expressed greater levels of E-selectin, ICAM-1,
and VCAM-1 than TECs cultured on hFN, with the presence of one definitive population. MHECs constitutively expressed ICAM-1 and VCAM-1, and MLECs
constitutively expressed ICAM-1. Activation of MHECs or MLECs with mTNF-a induced expression of E-selectin and further increased the expression of VCAM-1
and ICAM-1. OnFN-cultured TECs expressed similar levels of E-selectin as activated MHECs and greater levels of ICAM-1. These data are representative of three
similar experiments performed on separate days with different endothelial cultures. A minimum of 10,000 cells per sample was analyzed. All data were compared to
an isotype-matched control antibody to determine percent positive cells.
Table 1. Cell Surface Expression of Adhesion Molecules in MHECs and
TECs.
E-selectin ICAM-1 VCAM-1
Endothelium % Positive mcf % Positive mcf % Positive mcf
MHEC 2 5 63 71 83 107
MHEC+mTNF-a 41 57 80 238 98 312
MLEC 3 7 90 212 38 22
MLEC+mTNF-a 46 52 90 251 65 81
TEC human fibronectin 62 25 66 11 60 25
TEC oncofetal fibronectin 97 49 97 604 98 62
MHECs or MLECs plated on collagen IV/OnFN at subculture 1 were
incubated in the presence or absence of 120 ng/ml mTNF-a. TECs at
subculture 1 were plated on either collagen IV + hFN, or on collagen
IV+OnFN. ECs were analyzed by flow cytometry for cell surface expression
of E-selectin, ICAM-1, or VCAM-1, as described in Materials and Methods
section. A minimum of 10,000 cells per sample was analyzed. Results are
representative of three similar experiments performed on separate cultures.
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Figure 6. TECs exhibit different cellular distributions of endothelial molecules than normal MHECs. TECs or MHECs were plated at subculture 2 onto glass
coverslips precoated with either OnFN or hFN, respectively. At 2 days postconfluence, the cells were washed with DPBS+ and fixed in ice-cold methanol for 5 min
at  20jC. Cell surface adhesion molecules (CD31, b-catenin, ICAM-2, and VCAM-1) were stained with specific antibodies as described in Materials and Methods
section and detected with antirat or antirabbit IgG conjugated to Texas Red or FITC. Fluorescence images were captured on an Axiovert inverted microscope
equipped for fluorescence using a cooled CCD camera and IP Laboratories software. All images displayed were captured with a  40 objective. These images are
representative of three separate cultures of both MHECs and TECs generated from different source tissues at different times. Images of MHECs are shown in the
left hand panels (a,c,e,g) and of TECs in the right hand panels (b,d,f,g) with staining for CD31 (a,b), b-catenin (c,d), ICAM-2 (e,f), and VCAM-1 (g,h). Junctional
staining of CD31 and b-catenin was discontinuous in TECs, indicating the presence of fewer cell – cell junctions. In addition, VCAM-1 did not localize to cell – cell
junctions in TECs. In contrast, normal MHECs showed continuous junctional staining for CD31, b-catenin, and VCAM-1. There was little difference in distribution of
ICAM-2 between MHECs and TECs.
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of the molecules examined; however, there were significant
differences in the cellular distribution of particular molecules.
In both MHECs and TECs, CD31 was localized to cell–cell
junctions (Figure 6, panels a and b); however, in MHECs,
CD31 staining appeared continuous at these cell–cell inter-
faces (Figure 6, panel a), whereas CD31 did not form a
continuous band at the cell junctions of TECs. Instead, there
were numerous gaps present and punctate staining was
observed across the apical surface of the cells (Figure 6,
panel b). A similar pattern of expression was observed for h-
catenin staining (Figure 6, panels c and d ). MHECs demon-
strated continuous junctional localization of h-catenin,
whereas staining for h-catenin was discontinuous in TECs,
with some punctate staining present. The discontinuity of
both CD31 and h-catenin staining is indicative of poor cell–
cell contacts in TEC, and suggests the presence of limited
cell–cell junctions and greater permeability than observed
for normal MHECs. This would be consistent with the behav-
ior of tumor endothelium in vivo, which are considerably
more leaky than normal endothelium [5]. In contrast to
CD31 and h-catenin, the distribution of ICAM-2 was similar
in both normal MHECs and TECs (Figure 6, panels e and f ),
with diffuse staining observed across the cell, excluding the
nucleus, consistent with similar levels of expression
observed by FACS analysis. VCAM-1 expression was par-
tially localized to cell–cell junctions in normal MHECs, with
some diffuse staining (Figure 6, panel g); however, there was
no such localization observed in TECs, which demonstrated
only diffuse staining of VCAM-1 across the cell (Figure 6,
panel h), consistent with the decreased expression levels
observed by FACS analysis (Figure 5).
Discussion
The goal of this study was to identify inherent characteristics
of tumor-derived endothelium that may provide targets for
possible therapeutics or imaging agents. As part of this
approach, it was necessary to devise methods for the iso-
lation of tumor-derived endothelium in high purity from a
renewable source and maintenance of the tumor endothelial
phenotype in vitro. Previously described methods for isola-
tion of tumor-derived endothelium have been successful in
isolating tumor-derived ECs [13,14], but have failed to pro-
duce either adequate numbers of cells for additional studies,
or demonstrated an ability to maintain cultures of these cells
in vitro. Increasingly, investigators are making use of murine
models for in vivo studies, facilitated by the exponential rise
in transgenic mice available and the ability to easily manip-
ulate these animals at both the macro and molecular level.
There is a requirement, therefore, for species-matched
endothelium from both normal and tumor tissues. Previously,
we described new methods for the isolation and culture of
high-purity ECs from murine cardiac and pulmonary tissues
[18], and we extend this approach here to provide new
sources for both species and strain-matched tumor-derived
endothelium that can be used for extensive in vitro studies.
Gene expression varies considerably not only between
endothelia derived from the same tissue, but from different
mouse strains (e.g., C57Bl/6 versus 129SvEv), as demon-
strated by cell surface adhesion molecule expression [18] or
cytokine production. It was imperative, therefore, to compare
a model of tumor endothelium with a normal control, derived
from the same strain, eliminating any potential differences
due simply to strain differences. To achieve this goal, we
made use of an LLC cell line derived from a C57Bl/6 mouse,
implanted the tumors in C57Bl/6 mice, and used the same
strain as a source for our normal murine cardiac or pulmo-
nary endothelium.
To maintain the phenotype of TECs in vitro, it was
considered essential to recreate the environment found
within the tumor, and thus we devised specific culture con-
ditions that aimed to mimic the tumor environment in vitro.
First, we conditioned the TEC medium with LLC cells in vitro
for 3 days prior to use for TEC culture in an attempt to provide
essential growth factors (e.g., VEGF or bFGF) at approx-
imately the concentrations found in the tumor. Second, as
demonstrated above (Figure 2), the presence of the oncofe-
tal form of fibronectin was essential in maintaining cultures of
TEC. Surprisingly, in the absence of OnFN (but in the
presence of the native FN isoform), TECs proliferated rap-
idly, detached from the substrate (Figure 2), and abruptly lost
expression of all endothelial markers (Figure 3), appearing to
de-differentiate to a more primitive phenotype. Normal
MHECs or MLECs did not require the oncofetal isoform of
FN for in vitro culture, but could be cultured in the presence of
native FN. Furthermore, unlike for TECs (Figures 3 and 5),
cell surface adhesion molecule expression was not affected
by the extracellular matrix substrate or the presence of
medium optimized for tumor growth including VEGF.
Together, these data suggest that the FN receptor in tumor
ECs may contain a specific binding site for OnFN, but yet is
either unable to bind to the native form, or unable to trans-
duce signals through a5h1-integrin (FN receptor) as a result
of binding native FN. In addition, the apparent loss of
terminal differentiation and reversion to a more primitive
phenotype suggests that signaling through this epitope of
a5h1-integrin may influence gene expression within these
cells by providing a means for the cell to recognize its
location as being within the tumor vasculature.
Alternatively, a recent study [26] has indicated that FN
contains at least two binding domains for VEGF, and that
binding of VEGF to FN modulates the activity of VEGF,
promoting EC migration and MAP kinase activity. The coop-
eration of VEGF with the FN receptor may contribute to the
growth of TEC in culture and may explain the difference in
TEC phenotype observed on native FN or OnFN in one of
two ways, either 1) directly in which VEGF binds to OnFN
and cooperates through a5h1-integrin to induce signals
essential to endothelial growth, or 2) native FN may bind
large amounts of VEGF and instead ‘‘overstimulate’’ the
proliferation of TECs, resulting in their rapid proliferation,
migration, and de-differentiation. If the second is true, one
might expect MHECs or MLECs to behave in a similar
manner when plated on native FN; however, the levels of
VEGF present in the culture medium are likely to be much
lower than those present in the medium for TECs, and may
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be below the threshold to induce this rapidly proliferating
phenotype.
When we examined the cell surface expression of a
number of adhesion molecules and endothelial markers,
the most notable difference observed was in Sca-1 expres-
sion. TECs expressed much greater levels of Sca-1 on their
cell surface than those observed on MHECs or MLECs. Sca-
1 is the murine equivalent of human CD34, and is found on
hematopoietic cells, bone marrow–derived cells, and a
number of precursor or stem cells. The high level of expres-
sion of Sca-1 on TECs may indicate that the population is
derived largely from the recruitment of EC progenitors from
the circulation into the existing vascular structure by adult
vasculogenesis, whereas the relatively low level of Sca-1
expression on MHECs or MLECs may indicate a vascular
growth pattern by angiogenesis with little or no recruitment of
EC precursors. This explanation is certainly consistent with
the recent reports of the recruitment of circulating EC pro-
genitors to actively growing vascular sites, such as wounds
or tumors [21,27,28]. It is also possible, however, that
expression of Sca-1 could be turned on in culture as part of
a pattern of de-differentiation in which the cells revert to a
more primitive phenotype. If the latter were true, one might
expect an even greater level of expression of Sca-1 on TECs
cultured in the presence of native FN, which lose their
endothelial identity in culture; however, when Sca-1 expres-
sion in these cells was compared to TECs cultured on OnFN,
there was no significant difference (data not shown). It
remains unclear, therefore, whether high levels of Sca-1
expression do indeed indicate a primitive phenotype due to
recruitment of precursor cells during vasculogenesis in vivo,
or are induced during passage in vitro.
The TEC population was also >97% positive for Flk-1
(VEGFR-2) expression, compared with 22% of MHECs and
80% MLECs, and exhibited an expression level eight times
the maximum observed in multiple cultures of MHEC (Figure
4). This high level of VEGFR-2 cell surface expression on
TECs is consistent with the tumor environment in vivo;
indeed, LLC neovascularization in vivo requires VEGF, and
drugs or therapies that inhibit directly the VEGFR prevent
tumor growth and metastasis [29,30]. In the absence of
VEGF in vitro, TECs do not proliferate and eventually
undergo apoptosis (data not shown), confirming that the in
vivo tumor environment contains levels of VEGF that are
necessary for the maintenance of TECs.
TECs consistently demonstrated differences in morphol-
ogy (Figure 2) and increased levels of inducible adhesion
molecules when compared to MHECs or MLECs (Figure 5),
indicating that TECs were in a constitutively activated state.
In vivo, CD62E and ICAM-1 are expressed in areas of
inflammation such as in atherosclerosis or rheumatoid arthri-
tis [1,31]. and these molecules are critical in the recruitment
of circulating leukocytes to inflammatory sites. From the data
in Figure 1, it was apparent that LLC does indeed express
elevated levels of inducible adhesion molecules. Further-
more, previous data have indicated that within murine pros-
tate carcinoma in vivo [32], there are elevated levels of
selectins within the tumor, and expression of VCAM-1 in
murine melanoma appears to correlate with metastatic
potential [33], indicating that elevated levels of endothelial
adhesion molecules have a functional role in tumor endo-
thelium. These adhesion molecules may perform a similar
function, facilitating recruitment of bone marrow–derived or
circulating progenitor cells to the tumor vasculature, resulting
in neovascularization and tumor growth. Indeed, both E-
selectin and P-selectin (CD62P) can function as adhesion
molecules for CD34+ cells [34–36], mediating attachment
and rolling of these cells on multiple vascular beds, and it is
likely that other classic adhesion molecules may function
similarly within the tumor vasculature.
In a further investigation, we determined that the cellular
distribution of both CD31 and h-catenin in TECs was con-
sistent with the morphology observed under phase contrast
microscopy. Instead of a continuous ring of CD31 or adhe-
rens junctions around the cell periphery, as observed in
MHECs (Figure 6), the staining of both molecules contained
many gaps and punctate staining appeared across the cell
surface and within the cytoplasm. These data indicate that
TECs, at least in vitro, do not contain continuous junctional
contacts between neighboring cells, either through adherens
junctions or homotypic interactions of CD31 molecules. In
ECs, in the absence of tight junctions, the adherens junctions
are critical in maintaining cell–cell contact, controlling vas-
cular permeability [37], and mediating EC motility [38]. This
lack of stable cell–cell contacts therefore undoubtedly con-
tributes to the increased permeability observed in tumor
vasculature, and may contribute to both the motility of
resident ECs and the recruitment of circulating cells into
the existing vascular bed.
It has become apparent from recent studies that angio-
genesis and vasculogenesis play a critical role in tumor
growth and metastasis, and that these processes provide
ideal targets for new therapies. Unfortunately, the behavior
of different tumors in response to therapy varies consider-
ably and there is an increasing need to understand the
biology of a variety of tumors and tumor endothelium. Just
as the isolation of human umbilical vein ECs made it possible
to tease apart critical endothelial mechanisms of inflamma-
tion, atherosclerosis, and similar pathologies, this model
provides an ideal system for investigating the biology of
LLC endothelium in vitro. Understanding the role of tumor
endothelium in critical tumor processes has the potential to
identify new targets for cancer therapies. In addition, the
isolation of endothelium from other cancers and the identi-
fication of specific targets on each of the cell types may allow
us to determine which cancers will respond to which thera-
pies and to improve future treatment protocols for cancer
patients. Importantly, the in vitro nature of this model will
allow us to develop high throughput screening mechanisms
to evaluate potential drugs, imaging markers, viral delivery
methods, and similar products, in a manner that eliminates
expensive systematic in vivo screenings in small animals.
One notable problem with screening potential drugs in
animals is that they rarely have the same dosimetry or effect
in humans. This in vitro model may allow us to isolate and
culture endothelium from human tumors and use these cells
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for in vitro screens, thereby circumventing the inherent
problem of cross-species specificity and providing a more
direct analysis of the effects of these products on human
tissue.
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